TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10447904

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion in conjunction with epidural ropivacaine and isoflurane anaesthesia
Number of subjects: 0
Study: 7599325

Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell activity against K562 cells in children from contaminated areas
Number of subjects: 713

Group type: COMPARATOR
Intervention: Comparative analysis of NK cell activity in children from contaminated vs non-contaminated areas
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Correlation analysis of NK cell activity and number
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Correlation analysis of NK cell activity and body content of 137Cs
Number of subjects: 713
Study: 2083041

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2% copolymer)
Number of subjects: 108
Study: 6775827

Group type: EXPERIMENTAL
Intervention: Cytoxan
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 59
Study: 30884045

Group type: EXPERIMENTAL
Intervention: P11‐4 (Curodont Repair, Credentis AG, Switzerland)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CPP‐ACFP (MI Varnish, GCCo., Japan)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NaF (Duraphat Varnish, Colgate, Colgate‐Palmolive, NY, USA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Artificial saliva (control)
Number of subjects: 32
Study: 30449440

Group type: EXPERIMENTAL
Intervention: Wristband acupressure at P6 Neiguan point applied during the first 12 hours after operation
Number of subjects: 97

Group type: COMPARATOR
Intervention: Antiemetics during and after operation
Number of subjects: 97
Study: 28215665

Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab (8 mg/kg IV once, then 6 mg/kg every 3 weeks)
Number of subjects: 5099

Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab (8 mg/kg IV once, then 6 mg/kg every 3 weeks)
Number of subjects: 5099

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 5099

Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab
Number of subjects: 5099

Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab
Number of subjects: 5099
Study: 26284747

Group type: EXPERIMENTAL
Intervention: Free Glasses
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Voucher for Free Glasses
Number of subjects: 3001

Group type: COMPARATOR
Intervention: Control (Glasses Prescriptions Only)
Number of subjects: 3001
Study: 23401923

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 60
Study: 21651803

Group type: EXPERIMENTAL
Intervention: EARS II (HP® iPAQ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pen and Paper (P&P)
Number of subjects: 12
Study: 18513526

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CCR)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 770
Study: 16580575

Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate (25, 100, or 400 mg)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Extended-release felodipine (2.5, 10, or 20 mg)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Combination of extended-release metoprolol succinate and extended-release felodipine (various combinations)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Low-dose combination (ER metoprolol succinate 25 mg/ER felodipine 2.5 mg)
Number of subjects: 1092
Study: 12664053

Group type: EXPERIMENTAL
Intervention: Surface modifying additives (SMA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Untreated circuits (Control)
Number of subjects: 76
Study: 10669338

Group type: EXPERIMENTAL
Intervention: HIV human hyperimmune immunoglobulin (HIVIG) 200 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIV human hyperimmune immunoglobulin (HIVIG) 400 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIV human hyperimmune immunoglobulin (HIVIG) 800 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 9336105

Group type: EXPERIMENTAL
Intervention: Pack A
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pack B
Number of subjects: 10
Study: 8403783

Group type: EXPERIMENTAL
Intervention: Angiotensin II (0, 1, 2, 5, or 10 ng min-1 kg-1)
Number of subjects: 7
Study: 3542271

Group type: EXPERIMENTAL
Intervention: JM8
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: JM9
Number of subjects: 16
Study: 31764842

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 60
Study: 29990671

Group type: EXPERIMENTAL
Intervention: Culturally targeted decision aids (DAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic decision aids (DAs)
Number of subjects: 0
Study: 27887610

Group type: COMPARATOR
Intervention: m-health group using BENECA app for 2 months with usual care information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: integral group using BENECA app and face-to-face rehabilitation for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: integral group
Number of subjects: 0

Group type: COMPARATOR
Intervention: m-health group
Number of subjects: 0
Study: 1593359

Group type: COMPARATOR
Intervention: Furosemide (1 mg/kg per dose) intravenously every 24 hours for five doses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg per dose) with metolazone (0.2 mg/kg per dose) enterally with doses 3 and 4 of furosemide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Metolazone (0.2 mg/kg per dose) enterally every 24 hours for five doses
Number of subjects: 22
Study: 22450530

Group type: EXPERIMENTAL
Intervention: 400 ml of oral 12.5% carbohydrate solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo beverage (flavoured water)
Number of subjects: 60
Study: 20408061

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both ACT and CBT
Number of subjects: 104
Study: 18690345

Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) + trimegestone (0.5 mg)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Estradiol (2 mg) + dydrogesterone (10 mg)
Number of subjects: 186
Study: 15720047

Group type: EXPERIMENTAL
Intervention: Semi-urban villages
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Rural villages
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Salt consumption
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Salt added at the table
Number of subjects: 1013
Study: 12875749

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Antiarrhythmic medications
Number of subjects: 1171
Study: 10476903

Group type: EXPERIMENTAL
Intervention: No barrier membrane (Group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Occlusive resorbable collagen membrane (Group B)
Number of subjects: 29
Study: 8961473

Group type: EXPERIMENTAL
Intervention: Monomicrobial SBE
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Polymicrobial SBE
Number of subjects: 134

Group type: COMPARATOR
Intervention: Quinolones prophylaxis
Number of subjects: 134
Study: 2646332

Group type: EXPERIMENTAL
Intervention: CPC-detergent foam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 14
Study: 1111446

Group type: EXPERIMENTAL
Intervention: Staphylococcal clumping test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic heparin or aspirin
Number of subjects: 0
Study: 30795734

Group type: EXPERIMENTAL
Intervention: SNPs selected based on FST scores
Number of subjects: 2

Group type: COMPARATOR
Intervention: Randomly selected 20 K SNP subsets
Number of subjects: 2

Group type: COMPARATOR
Intervention: All 400 K SNPs
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 80 K SNPs selected based on FST scores
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 40 K SNPs selected based on FST scores
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 20 K SNPs selected based on FST scores
Number of subjects: 2
Study: 28859646

Group type: EXPERIMENTAL
Intervention: Usual care plus a decision aid (DA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 128
Study: 25403844

Group type: EXPERIMENTAL
Intervention: SNP group
Number of subjects: 111

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Acting out defensive style and BDI
Number of subjects: 111
Study: 22330131

Group type: EXPERIMENTAL
Intervention: HCl infusion (0.15 M for 30 minutes)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 21
Study: 21487259

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18827611

Group type: EXPERIMENTAL
Intervention: Oral plus written information
Number of subjects: 102

Group type: COMPARATOR
Intervention: Oral information only
Number of subjects: 102
Study: 21182550

Group type: EXPERIMENTAL
Intervention: Coping episodes
Number of subjects: 372
Study: 15927054

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy‐‐General
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Functional Living Index‐‐Cancer
Number of subjects: 1277
Study: 12455679

Group type: EXPERIMENTAL
Intervention: Frontal lobe damage (patients with unilateral frontal lobe lesions)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Young control subjects
Number of subjects: 3
Study: 9538308

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metoprolol CR (100 mg once daily)
Number of subjects: 50
Study: 8273968

Group type: EXPERIMENTAL
Intervention: Technetium-99m-sestamibi localization
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no preoperative radionuclide scanning)
Number of subjects: 42
Study: 2658454

Group type: COMPARATOR
Intervention: Sandostatin (100 micrograms)
Number of subjects: 10
Study: 66331

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29239259

Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 120
Study: 27605629

Group type: EXPERIMENTAL
Intervention: ISIS 388626 (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISIS 388626 (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISIS 388626
Number of subjects: 0
Study: 23892729

Group type: COMPARATOR
Intervention: Standard swallowing exercises (N = 14)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System™ swallowing exercises (N = 15)
Number of subjects: 29
Study: 21239075

Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel (150 mg/day for 1 month)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (75 mg/day for 1 month)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (75 mg/day for 1 month)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 192
Study: 20148806

Group type: EXPERIMENTAL
Intervention: Allergen nasal challenge
Number of subjects: 22

Group type: COMPARATOR
Intervention: CCR4 antagonist
Number of subjects: 22
Study: 18719447

Group type: EXPERIMENTAL
Intervention: Combined sciatic (single‐shot) and continuous femoral block (48 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine patient‐controlled analgesia
Number of subjects: 0
Study: 16115358

Group type: EXPERIMENTAL
Intervention: CLA-enriched dairy products (1.43 g c9,t11 CLA/d; 4.71 g tVA/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dairy products (0.17 g c9,t11 CLA/d; 0.31 g tVA/d)
Number of subjects: 0
Study: 12464460

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10051075

Group type: EXPERIMENTAL
Intervention: Prone position with inhaled nitric oxide (10 ppm)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Inhalation of nitric oxide (10 ppm) in supine position
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of prone position and inhaled nitric oxide
Number of subjects: 14
Study: 7549052

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 121

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 121
Study: 2268124

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: CT and MRI combined
Number of subjects: 202
Study: 285821

Group type: EXPERIMENTAL
Intervention: Stab wounds over the roots of the incisors
Number of subjects: 31

Group type: COMPARATOR
Intervention: Papillar wounds inflicted at the same level
Number of subjects: 31
Study: 31807849

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) with paclitaxel
Number of subjects: 137

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) ± bare metal stenting (BMS)
Number of subjects: 137
Study: 30721635

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 52
Study: 29084657

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pefloxacin
Number of subjects: 160
Study: 26530931

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 40 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cathodal tDCS (2 mA, 40 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 9
Study: 23462319

Group type: EXPERIMENTAL
Intervention: Obese individuals with binge eating disorder (BED)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Non-BED obese individuals (OB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Lean control subjects (LC)
Number of subjects: 57
Study: 21251129

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (positive control drug)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo-baseline-adjusted QTc prolongation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HA-QT vs FDA-approved measurements
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Moxifloxacin-induced QTc prolongation adjusted for placebo
Number of subjects: 7
Study: 18534397

Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty (CAS)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty (CONV)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Patients with coronal alignment within 3 degrees of neutral
Number of subjects: 115
Study: 17868736

Group type: EXPERIMENTAL
Intervention: Laparoscopic live donor nephrectomy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Open live donor nephrectomy
Number of subjects: 69
Study: 12898456

Group type: EXPERIMENTAL
Intervention: Alanine (1.5 mg. kg(‐1). min(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (unlabeled glucose at 22 micromol. kg(‐1). min(‐1))
Number of subjects: 11
Study: 10889425

Group type: EXPERIMENTAL
Intervention: First-generation silicone lens
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 3-piece acrylic lens
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 3-piece second-generation silicone lens
Number of subjects: 128

Group type: COMPARATOR
Intervention: Overall comparison of lens designs
Number of subjects: 128
Study: 8744911

Group type: EXPERIMENTAL
Intervention: Criteria proposed by patients
Number of subjects: 344

Group type: COMPARATOR
Intervention: Criteria proposed by dentists
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Patient criteria
Number of subjects: 344

Group type: COMPARATOR
Intervention: Dentist criteria
Number of subjects: 344
Study: 1417015

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 42
Study: 3904885

Group type: EXPERIMENTAL
Intervention: Sulpiride (2000 mg/day, range 800-3200)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Haloperidol (12 mg/day, range 6-24)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sulpiride and Haloperidol
Number of subjects: 20
Study: 30797750

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment for patients with thyroid-stimulating hormone values of more than 10 mIU/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of therapy for abnormal thyroid function
Number of subjects: 0
Study: 30003561

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 131
Study: 26882833

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg of 5% ketamine)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg of 2% lidocaine)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study: 25423698

Group type: EXPERIMENTAL
Intervention: Breast conserving surgery (BCS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Total mastectomy (TM)
Number of subjects: 61
Study: 23093664

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.3 units · kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.6 units · kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin glargine (1.2 units · kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metabolite M2
Number of subjects: 12
Study: 19969374

Group type: EXPERIMENTAL
Intervention: Sertraline plus atomoxetine (40‐120 mg/d)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 261

Group type: COMPARATOR
Intervention: Sertraline monotherapy
Number of subjects: 261
Study: 17850609

Group type: EXPERIMENTAL
Intervention: simplified papilla preservation
Number of subjects: 10

Group type: COMPARATOR
Intervention: modified Widman flap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: both surgical modalities
Number of subjects: 10
Study: 16127520

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Lanolin
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 225
Study: 11938346

Group type: EXPERIMENTAL
Intervention: Hydrocolloid A
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hydrocolloid B
Number of subjects: 31
Study: 9660375

Group type: EXPERIMENTAL
Intervention: 30 mg of oral d‐fenfluramine (d‐FEN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7640447

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage with intravenous antibiotic therapy (aminoglycoside and cephem)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Silicon tube drainage with the same systemic antibiotic therapy
Number of subjects: 53
Study: 2751138

Group type: EXPERIMENTAL
Intervention: 6 mg tetracaine with 0.2 mg epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6 mg tetracaine alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg tetracaine
Number of subjects: 60
Study: 319123

Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride (SERC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30538075

Group type: EXPERIMENTAL
Intervention: Telmisartan co-administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29401318

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 44

Group type: COMPARATOR
Intervention: No drug (Control)
Number of subjects: 44
Study: 27080379

Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine (100μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAP block (ultrasound-guided)
Number of subjects: 0
Study: 25052334

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patches for four weeks before quitting, whilst smoking as normal
Number of subjects: 1786

Group type: COMPARATOR
Intervention: Not using nicotine patches
Number of subjects: 1786
Study: 22429384

Group type: EXPERIMENTAL
Intervention: Decision aid for service choices
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 31
Study: 19726362

Group type: EXPERIMENTAL
Intervention: PA‐MSHA treatment in addition to neoadjuvant chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with neoadjuvant chemotherapy
Number of subjects: 60
Study: 17954801

Group type: EXPERIMENTAL
Intervention: 2% CHG-impregnated washcloths (Sage 2% CHG cloths)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 836
Study: 15010094

Group type: EXPERIMENTAL
Intervention: Planned Codes with strategies
Number of subjects: 156

Group type: COMPARATOR
Intervention: Planned Codes with speed
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Correlation between scores under both conditions
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Effect size between the two groups
Number of subjects: 156
Study: 11684980

Group type: COMPARATOR
Intervention: Air-filled cuff (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Saline-filled cuff (group S)
Number of subjects: 50
Study: 9893549

Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms.ml‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mixture of bupivacaine and sufentanil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sufentanil alone
Number of subjects: 45